Board of Directors


Kathryn M. Baker

Kathryn has 35 years of experience in strategy, finance, business development and leadership and has held over 30 significant board positions. Until 2020, Ms. Baker served on the Executive Board of the Central Bank of Norway (Norges Bank), where she was also a member of the Audit and Risk and Investment Committees.

Ms. Baker currently serves on the Boards of Akastor ASA, DOF ASA, Hudya AB and Labrida and is a member of the Investment Committee at Norfund. She has previously served as Chairman of Catena Media Plc, Navamedic ASA and Agasti ASA as well as the Norwegian Private Equity and Venture Capital Association (NVCA).

Ms. Baker was previously a partner at the Norwegian private equity firm Reiten & Co for 15 years and has held positions with Morgan Stanley and McKinsey. She holds a bachelor’s degree in economics from Wellesley College and an MBA from Dartmouth’s Tuck School of Business.

Board Member

Camilla Huse Bondesson

Camilla holds an Executive MBA from Stockholm University and is currently Chairman of the Board of Immuneed AB and TdB Labs AB. Camilla has over 30 years of international operational and strategic experience from leading positions in companies in the biotechnology field, including as head of Behring Diagnostica AB, international product manager for Biacore, marketing manager for Amersham Biosciences (now Cytiva) and VP Marketing for Gyros AB.

Since 2004, Camilla has worked as a consultant and partner at Conlega, a consulting company focusing on Life Science.

Board Member

Staffan Strömberg

Staffan holds a PhD from KTH Royal Institute of Technology in Stockholm and has over 23 years of experience in the pharmaceutical industry. He is currently CEO of Infant Bacterial Therapeutics AB.
Besides his role as Head of Medical Devices at the Swedish Medical Products Agency, he has also been Vice President of Nicox France, and had management positions at AstraZeneca.

Staffan has particularly experience in the development of orphan drugs as he was Head of R&D of Swedish Orphan.

Board Member

Ashok K. Shah

Ashok holds an MBA from McGill University in Canada, and a bachelor’s degree in Microbiology. He has more than 30 years of international experience in the sector both from executive management positions and from senior roles.

Ashok has held positions with Becton-Dickinson, Fisher Scientific, IMS Health, and as CEO of a successful start-up. He currently holds the position as Vice President in the Corporate Strategy Team in Bio-Rad Inc where he is focused on identifying new technologies, products, and acquisition targets.

Board Member

Rune Sørum

Rune holds a Master of Science in Business and Economics (siviløkonom) from Copenhagen School of Economics and Business Administration. He is a Norwegian citizen with residence in Oslo, Norway. Rune is currently a Partner in Televenture Management.

Before joining Televenture, Rune was a private investor and a senior adviser for European companies working in both Asia and the Middle East.
Rune has held several board positions in Norwegian investment companies.